Translating cell-based regenerative medicines from research to successful products: challenges and solutions.

The Tissue Engineering & Regenerative Medicine International Society-Europe (TERMIS-EU) Industry Committee as well as its TERMIS-Americas (AM) counterpart intend to address the specific challenges and needs facing the industry in translating academic research into commercial products. Over the last 3 years, the TERMIS-EU Industry Committee has worked with commercial bodies to deliver programs that encourage academics to liaise with industry in proactive collaborations. The TERMIS-EU 2013 Industry Symposium aimed to build on this commercial agenda by focusing on two topics: Operations Management (How to move a process into the good manufacturing practice [GMP] environment) and Clinical Translation (Moving a GMP process into robust trials). These topics were introduced by providing the synergistic business perspective of partnering between the multiple regenerative medicine stakeholders, throughout the life cycle of product development. Seven industry leaders were invited to share their experience, expertis...

[1]  J. Hagedoorn.  Inter-firm R&D partnerships: an overview of major trends and patterns since 1960 , 2002 .

[2]  Michael Ringel,et al.  What matters most in commercial success: first-in-class or best-in-class? , 2013, Nature Reviews Drug Discovery.

[3]  M. Sculpher,et al.  Using Value of Information Analysis to Prioritise Health Research , 2012, PharmacoEconomics.

[4]  Noel P. Greis,et al.  External partnering as a response to innovation barriers and global competition in biotechnology , 1995 .

[5]  Alan J Girling,et al.  Modeling payback from research into the efficacy of left-ventricular assist devices as destination therapy , 2007, International Journal of Technology Assessment in Health Care.

[6]  Ning Wang,et al.  Is there complementarity or substitutability between internal and external R&D strategies? , 2012 .

[7]  Richard Lilford,et al.  Early-stage valuation of medical devices: the role of developmental uncertainty. , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[8]  A. Girling,et al.  Pricing of medical devices under coverage uncertainty--a modelling approach. , 2012, Health economics.

[9]  Paul Kemp,et al.  History of regenerative medicine: looking backwards to move forwards. , 2006, Regenerative medicine.

[10]  D. Supp,et al.  Engineered skin substitutes: practices and potentials. , 2005, Clinics in dermatology.

[11]  S. E. James,et al.  A review of tissue-engineered skin bioconstructs available for skin reconstruction , 2010, Journal of The Royal Society Interface.

[12]  Arshad Ahmed,et al.  Commercialization of regenerative products: the academic/industry partnership. , 2014, Tissue engineering. Part B, Reviews.

[13]  Peter Wood,et al.  Cost‐effectiveness analysis at the development phase of a potential health technology: examples based on tissue engineering of bladder and urethra , 2007, Journal of tissue engineering and regenerative medicine.

[14]  Steven S. Oh,et al.  Considerations for tissue-engineered and regenerative medicine product development prior to clinical trials in the United States. , 2010, Tissue engineering. Part B, Reviews.

[15]  I. Yannas,et al.  Design of an artificial skin. I. Basic design principles. , 1980, Journal of biomedical materials research.

[16]  E Bell,et al.  Production of a tissue-like structure by contraction of collagen lattices by human fibroblasts of different proliferative potential in vitro. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Richard J. Lilford,et al.  Investing in new medical technologies: A decision framework , 2007 .

[18]  Rob Stringer,et al.  How to Manage Radical Innovation , 2000 .

[19]  Robert J Snyder,et al.  Spray-applied cell therapy with human allogeneic fibroblasts and keratinocytes for the treatment of chronic venous leg ulcers: a phase 2, multicentre, double-blind, randomised, placebo-controlled trial , 2012, The Lancet.